CV Sciences (OTCMKTS:CVSI – Get Free Report) and Stoke Therapeutics (NASDAQ:STOK – Get Free Report) are both small-cap medical companies, but which is the superior business? We will contrast the two businesses based on the strength of their institutional ownership, analyst recommendations, valuation, profitability, risk, dividends and earnings.
Analyst Ratings
This is a breakdown of recent ratings and recommmendations for CV Sciences and Stoke Therapeutics, as reported by MarketBeat.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| CV Sciences | 0 | 0 | 0 | 0 | 0.00 |
| Stoke Therapeutics | 0 | 1 | 7 | 1 | 3.00 |
Stoke Therapeutics has a consensus target price of $20.83, suggesting a potential upside of 49.66%. Given Stoke Therapeutics’ stronger consensus rating and higher possible upside, analysts clearly believe Stoke Therapeutics is more favorable than CV Sciences.
Volatility and Risk
Profitability
This table compares CV Sciences and Stoke Therapeutics’ net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| CV Sciences | -15.95% | -89.87% | -27.94% |
| Stoke Therapeutics | -629.90% | -54.45% | -40.77% |
Earnings & Valuation
This table compares CV Sciences and Stoke Therapeutics”s revenue, earnings per share and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| CV Sciences | $16.00 million | 0.49 | $3.10 million | ($0.01) | -4.27 |
| Stoke Therapeutics | $16.74 million | 44.04 | -$104.70 million | ($2.10) | -6.63 |
CV Sciences has higher earnings, but lower revenue than Stoke Therapeutics. Stoke Therapeutics is trading at a lower price-to-earnings ratio than CV Sciences, indicating that it is currently the more affordable of the two stocks.
Summary
Stoke Therapeutics beats CV Sciences on 8 of the 13 factors compared between the two stocks.
About CV Sciences
CV Sciences, Inc. develops, manufactures, markets, and sells herbal supplements and hemp-based cannabidiol (CBD) in North America. It operates in two segments, Consumer Products and Specialty Pharmaceutical. The company offers its products under the PlusCBD, ProCBD, HappyLane, CVAcute, CVDefense, and PlusCBD Pet brands in the health care market sector, including nutraceutical, beauty care, specialty foods, and pet products through its websites, elect distributors, brick and mortar retailers, and select e-tailers. It is also developing cannabinoids intended to treat medical indications, including CVSI-007 that combines CBD and nicotine for the treatment of smokeless tobacco use and addiction. The company was formerly known as CannaVest Corp. and changed its name to CV Sciences, Inc. in January 2016. CV Sciences, Inc. was incorporated in 2010 and is based in San Diego, California.
About Stoke Therapeutics
Stoke Therapeutics, Inc., an early-stage biopharmaceutical company, develops medicines to treat the underlying causes of severe genetic diseases in the United States. The company utilizes its proprietary targeted augmentation of nuclear gene output to develop antisense oligonucleotides to selectively restore protein levels. Its lead clinical candidate is STK-002, which is in preclinical stage for the treatment of autosomal dominant optic atrophy. The company also develops STK-001, which is in phase I/II clinical trial to treat Dravet syndrome; and programs focused on multiple targets, including haploinsufficiency diseases of the central nervous system and eye. The company has a license and collaboration agreement with Acadia Pharmaceuticals Inc. for the discovery, development, and commercialization of novel RNA-based medicines for the treatment of severe and rare genetic neurodevelopmental diseases of the central nervous system. The company was formerly known as ASOthera Pharmaceuticals, Inc. and changed its name to Stoke Therapeutics, Inc. in May 2016. Stoke Therapeutics, Inc. was incorporated in 2014 and is headquartered in Bedford, Massachusetts.
Receive News & Ratings for CV Sciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for CV Sciences and related companies with MarketBeat.com's FREE daily email newsletter.
